{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:35:46Z","timestamp":1784230546279,"version":"3.55.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100157"],"award-info":[{"award-number":["82100157"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.leukres.2025.107924","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:51:42Z","timestamp":1753728702000},"page":"107924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapies"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9381-948X","authenticated-orcid":false,"given":"Xinyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3048-2835","authenticated-orcid":false,"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2025.107924_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00291919","article-title":"A new chromosome anomaly in acute lymphoblastic leukemia (ALL)","volume":"46","author":"Van den Berghe","year":"1979","journal-title":"Hum. Genet."},{"key":"10.1016\/j.leukres.2025.107924_bib2","doi-asserted-by":"crossref","first-page":"10735","DOI":"10.1073\/pnas.88.23.10735","article-title":"Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias","volume":"88","author":"Ziemin-van der Poel","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.leukres.2025.107924_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0092-8674(92)90603-A","article-title":"The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene","volume":"71","author":"Gu","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2025.107924_bib4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0092-8674(00)81269-6","article-title":"An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes","volume":"85","author":"Corral","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2025.107924_bib5","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1093\/emboj\/16.14.4226","article-title":"Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL","volume":"16","author":"Lavau","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.leukres.2025.107924_bib6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2025.107924_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cncr.30376","article-title":"Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease","volume":"123","author":"Issa","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2025.107924_bib8","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood-2013-03-486647","article-title":"Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells","volume":"122","author":"Li","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib9","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2025.107924_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2025.107924_bib11","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/0008-5472.CAN-06-2369","article-title":"Interaction of MLL amino terminal sequences with menin is required for transformation","volume":"67","author":"Caslini","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2025.107924_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2025.107924_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1128\/MCB.21.1.224-234.2001","article-title":"Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia","volume":"21","author":"Thorsteinsdottir","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.leukres.2025.107924_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/378505a0","article-title":"Altered Hox expression and segmental identity in Mll-mutant mice","volume":"378","author":"Yu","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2025.107924_bib15","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/leu.2009.33","article-title":"New insights to the MLL recombinome of acute leukemias","volume":"23","author":"Meyer","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107924_bib16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107924_bib17","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/biomedicines9080924","article-title":"BTK, NUTM2A, and PRPF19 Are Novel KMT2A partner genes in childhood acute leukemia","volume":"9","author":"Zerkalenkova","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.leukres.2025.107924_bib18","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1101\/gad.1602107","article-title":"Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential","volume":"21","author":"Wong","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.leukres.2025.107924_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/0008-5472.CAN-15-1566","article-title":"PBX3 and MEIS1 cooperate in hematopoietic cells to drive acute myeloid leukemias characterized by a core transcriptome of the MLL-rearranged disease","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2025.107924_bib20","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1101\/gad.349284.121","article-title":"A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia","volume":"36","author":"Harada","year":"2022","journal-title":"Genes Dev."},{"key":"10.1016\/j.leukres.2025.107924_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"St. Jude Children\u2019s Research Hospital\u2013Washington University Pediatric Cancer Genome Project, the landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2025.107924_bib22","doi-asserted-by":"crossref","first-page":"26340","DOI":"10.1073\/pnas.2014732117","article-title":"Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A","volume":"117","author":"Bill","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.leukres.2025.107924_bib23","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.3390\/cancers13194817","article-title":"Impact of KMT2A rearrangement and CSPG4 expression in pediatric acute myeloid leukemia","volume":"13","author":"Hoffmeister","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2025.107924_bib24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41375-024-02333-4","article-title":"Rearrangements involving 11q23.3\/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study","volume":"38","author":"Hern\u00e1ndez-S\u00e1nchez","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107924_bib25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","article-title":"Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2025.107924_bib26","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2025.107924_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000785","article-title":"Duplex sequencing uncovers recurrent low-frequency cancer-associated mutations in infant and childhood KMT2A-rearranged acute leukemia","volume":"6","author":"Pilheden","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.leukres.2025.107924_bib28","first-page":"95","article-title":"LEDGF\/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis","volume":"131","author":"El Ashkar","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature10806","article-title":"The same pocket in menin binds both MLL and JUND but has opposite effects on transcription","volume":"482","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2025.107924_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.leukres.2025.107924_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","article-title":"Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1","volume":"13","author":"Fiskus","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2025.107924_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2025.107924_bib33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2025.107924_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A molecular switch between Mammalian MLL complexes dictates response to menin\u2013MLL inhibition","volume":"13","author":"Soto-Feliciano","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2025.107924_bib35","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/s41588-024-01874-9","article-title":"In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor-microenvironment interactions","volume":"56","author":"Su","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2025.107924_bib36","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.molcel.2022.02.013","article-title":"MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape","volume":"82","author":"Olsen","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.leukres.2025.107924_bib37","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3324\/haematol.2012.074195","article-title":"The trithorax protein partner menin acts in tandem with EZH2 to suppress C\/EBP\u03b1 and differentiation in MLL-AF9 leukemia","volume":"98","author":"Thiel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107924_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2025.107924_bib39","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1007\/s00432-023-04752-9","article-title":"Targeting the undruggable: menin inhibitors ante portas","volume":"149","author":"Dempke","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107924_bib40","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.3390\/ijms25116020","article-title":"Distinct responses to menin inhibition and synergy with DOT1L inhibition in KMT2A-rearranged acute lymphoblastic and myeloid leukemia","volume":"25","author":"Adriaanse","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.leukres.2025.107924_bib41","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood-2023-191216","article-title":"Single-cell proteomic analysis reveals menin inhibition-induced proteomic alterations in AML patients treated with revumenib","volume":"142","author":"Muftuoglu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2024-194384","article-title":"Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib43","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1182\/bloodadvances.2024015527","article-title":"Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia","volume":"9","author":"Okeleji","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2025.107924_bib44","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2025.107924_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107924_bib46","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","article-title":"Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1","volume":"36","author":"Fiskus","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107924_bib47","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2021-149831","article-title":"Clinical-stage menin inhibitor KO-539 Is synergistically active with multiple classes of targeted agents in KMT2A-r and NPM1-mutant AML models","volume":"138","author":"Davis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib48","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2025.107924_bib49","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood-2022-157225","article-title":"Preclinical in vivo activity of the menin inhibitor ziftomenib (KO-539) in pediatric KMT2A-rearranged acute lymphoblastic leukemia","volume":"140","author":"Falkenstein","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib50","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.285616","article-title":"Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia","author":"Hogeling","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107924_bib51","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","article-title":"Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead","volume":"17","author":"Nadiminti","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2025.107924_bib53","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1182\/blood-2023-173149","article-title":"Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R\/R) acute leukemia (AL): preliminary phase 1 data from the covalent-101 study","volume":"142","author":"Lancet","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 results: first-in-human phase 1\/2 study of the Menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib55","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2024-198959","article-title":"A first-in-human phase 1\/2 study of the menin-KMT2A(MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia","volume":"144","author":"Wu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib56","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2025.107924_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107777","article-title":"Drug-resistant menin variants retain high binding affinity and interactions with MLL1","volume":"300","author":"Ray","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2025.107924_bib58","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood-2024-208887","article-title":"Discerning the landscape of menin inhibitor resistance","volume":"144","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib59","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib60","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1182\/blood-2024-202042","article-title":"Discovery of BTC-86, a novel second-generation menin-MLL inhibitor to overcome the acquired resistance in MEN1 for R\/R acute leukemia","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114901","article-title":"NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML","volume":"43","author":"Heikamp","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.leukres.2025.107924_bib62","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2024-206624","article-title":"Transient menin inhibition is sufficient to induce irreversible polycomb-mediated silencing and potent anti-proliferative effects in MLL-rearranged AML","volume":"144","author":"Neville","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib63","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib64","doi-asserted-by":"crossref","first-page":"9341","DOI":"10.1038\/s41467-024-53399-8","article-title":"MLL oncoprotein levels influence leukemia lineage identities","volume":"15","author":"Janssens","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2025.107924_bib65","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2023-190475","article-title":"Komet-008: a phase 1 study to determine the safety and tolerability of ziftomenib combinations for the treatment of KMT2A-rearranged or NPM1-mutant relapsed\/refractory acute myeloid leukemia","volume":"142","author":"Goldberg","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2023-182337","article-title":"Early results of the phase I\/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE)","volume":"142","author":"Issa","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2024-207072","article-title":"Phase 1b study of menin-KMT2A inhibitor bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2Ar or NPM1 alterations","volume":"144","author":"Recher","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7079","article-title":"Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax\/azacitidine or standard induction cytarabine\/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia","volume":"41","author":"Zeidan","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.leukres.2025.107924_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.584974","article-title":"Targeting Bcl-2 proteins in acute myeloid leukemia","volume":"10","author":"Wei","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2025.107924_bib70","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2025.107924_bib71","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107924_bib72","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2014.72","article-title":"Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199","volume":"28","author":"Niu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107924_bib73","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","article-title":"Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax","volume":"108","author":"Rausch","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107924_bib74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40364-023-00547-9","article-title":"Repressing HIF-1\u03b1-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML","volume":"11","author":"Ling","year":"2023","journal-title":"Biomark. Res"},{"key":"10.1016\/j.leukres.2025.107924_bib75","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/blood-2024-199170","article-title":"Ziftomenib Combined with Venetoclax\/Azacitidine in Relapsed\/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007","volume":"144","author":"Fathi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib76","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib77","article-title":"Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"0","author":"Zeidner","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.leukres.2025.107924_bib78","doi-asserted-by":"crossref","first-page":"4265.2","DOI":"10.1182\/blood-2024-201582","article-title":"A multi-site break through cancer trial: phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib79","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/s41375-024-02368-7","article-title":"Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community","volume":"38","author":"Cuglievan","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107924_bib80","doi-asserted-by":"crossref","first-page":"1504.4","DOI":"10.1182\/blood-2024-208146","article-title":"A phase I study investigating the combination of the Ziftomenib, Venetoclax and Azacitidine (ZiVA) in pediatric relapsed and refractory acute leukemias","volume":"144","author":"McCall","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib81","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","article-title":"An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape","volume":"25","author":"Bystrom","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.leukres.2025.107924_bib82","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2025.107924_bib83","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.3324\/haematol.2014.105544","article-title":"K. D\u00f6hner, Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations","volume":"99","author":"K\u00fchn","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107924_bib84","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ng.3371","article-title":"The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias","volume":"47","author":"Lavall\u00e9e","year":"2015","journal-title":"Nat. Genet"},{"key":"10.1016\/j.leukres.2025.107924_bib85","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib86","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2024-198218","article-title":"Ziftomenib combined with intensive induction (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007","volume":"144","author":"Zeidan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib87","doi-asserted-by":"crossref","first-page":"4265.3","DOI":"10.1182\/blood-2024-204583","article-title":"APAL2020K\/ITCC-101: a phase I trial of the menin inhibitor Ziftomenib in combination with chemotherapy in children with relapsed\/refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias","volume":"144","author":"Salzer","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib88","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.leukres.2025.107924_bib89","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2025.107924_bib90","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib91","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2025.107924_bib92","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107924_bib93","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1182\/blood-2024-212075","article-title":"Potent target-specific efficacy of CAR T cells directed toward the AML and KMT2A-rearranged specific antigen CLEC2A","volume":"144","author":"Kirkey","year":"2024","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262500284X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262500284X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:55:26Z","timestamp":1772780126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262500284X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":93,"alternative-id":["S014521262500284X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107924","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapies","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107924"}}